Stocks and Investing
Stocks and Investing
Thu, December 9, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, December 8, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Derek Archila Initiated (ASND) at Buy and Held Target at $176 on, Dec 8th, 2021
Derek Archila of Wells Fargo, Initiated "Ascendis Pharma A/S" (ASND) at Buy and Held Target at $176 on, Dec 8th, 2021.
Derek has made no other calls on ASND in the last 4 months.
There are 4 other peers that have a rating on ASND. Out of the 4 peers that are also analyzing ASND, 1 agrees with Derek's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Tazeen Ahmad of "B of A Securities" Downgraded from Strong Buy to Hold and Increased Target to $169 on, Wednesday, October 20th, 2021
These are the ratings of the 3 analyists that currently disagree with Derek
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $190 on, Monday, November 15th, 2021
- Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $179 on, Thursday, November 11th, 2021
- David Lebowitz of "Morgan Stanley" Maintained at Buy with Increased Target to $204 on, Thursday, August 26th, 2021
Contributing Sources